Pituitary Disorders
US PITUITARY PARTNER
An Introduction to Pituitary Disorders
Pituitary disorders are rare and include acromegaly, adult growth hormone deficiency, craniopharyngioma, Cushing’s disease, diabetes insipidus, hypopituitarism, non-functioning tumours and prolactinoma. These conditions can be hard to diagnose, but advances in pituitary imaging technology and the development of intraoperative MRI have facilitated prompt detection. Treatments include pituitary hormone replacement, dopamine agonist therapy for the treatment of prolactin-secreting pituitary tumours and some growth hormone-secreting pituitary tumours, and somatostatin, octreotide and pegvisomant for the treatment of acromegaly. The approval of oral octreotide delayed-release capsules is set to transform the maintenance therapy of patients with acromegaly.
Browse our gallery of video highlights and short articles from the conference hub, providing the latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
The World Alliance of Pituitary Organizations (WAPO), a leading non-profit uniting pituitary patient advocates worldwide, has announced the launch of its Blogs & Vlogs 2025, an innovative initiative designed to amplify the voices of patients, experts and advocates around the world.
Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a range of review, case report and original research articles that highlight some key developments in our understanding and management of endocrinological disease. We begin with a commentary from ...
Cushing’s disease (CD) is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma, or rarely carcinoma, and is considered a highly morbid endocrine disorder with few medical options.1,2 Although transsphenoidal pituitary surgery (TSS) is the mainstay of treatment for ...
Acromegaly is a chronic disease caused by an excess of growth hormone (GH) and insulin-like growth factor 1 (IGF-1).1,2Â Besides facial and acral changes, systemic complications lead to decreased quality of life and survival rates.3Â The primary goal of acromegaly treatment ...
Watch leading experts Prof. Moshe Phillip, Dr Sandro Loche and Prof. Antonio de Arriba discuss challenges in growth hormone disease management, and how digital health tools and data analytics can support HCPs and improve outcomes for patients.
Osilodrostat, a novel potent oral steroidogenesis inhibitor, has recently been approved for the treatment of adult patients with endogenous Cushing’s syndrome (CS), and Cushing’s disease (CD) not cured by pituitary surgery or in whom pituitary surgery is not ...
Cushing’s disease (CD), or pituitary-dependent Cushing’s syndrome, is almost always caused by corticotroph tumours, a type of pituitary neuroendocrine tumour, which overproduces adrenocorticotrophic hormone (ACTH), ultimately leading to hypercortisolism and its associated clinical consequences, including increased mortality.1 The ...
Acromegaly is the clinical consequence of chronic excessive exposure of the tissues to growth hormone (GH) and its second messenger, insulin-like growth factor-I (IGF-I). The excess GH secretion is almost exclusively secondary to a GH-secreting pituitary adenoma (somatotropinomas); however, excess ...
In physiological conditions, the pituitary gland contributes to proper body functions and homeostasis. The assumed circadian rhythm of anterior pituitary hormones seems to be an important part of the hormonal balance. Cortisol release triggered by adrenocorticotropic hormone (ACTH) forms the ...
Craniopharyngiomas (CPs) are rare, benign, epithelial tumours of the sellar and parasellar regions arising as embryonic malformations along the pathway of the craniopharyngeal duct.1 They have an incidence of 0.13 per 100,000 per year to 0.5–2.0 per million per year and are classified ...
Oncocytomas are epithelial tumours composed of cells with eosinophilic, mitochondria-rich cytoplasm.1 They can occur in various organs, such as the kidneys, thyroid, pituitary gland, salivary glands and parathyroid glands. Rarely, it has been reported in the respiratory and gastrointestinal tracts.2–4 ...
The use of immunotherapy in the treatment of cancer has been revolutionary, opening a new era in the fight against cancer. The principle of immunotherapy involves using pharmacotherapy to harness the power of the body’s own immune system to ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
